Fredrik Jarrsten - Orexo AB Ex CFO

All Insiders . USA . 
Stock . Orexo AB ADR . Stakeholders . Insider . Fredrik Jarrsten
ORXOY Stock  USD 1.00  0.02  2.04%   

Insider

Fredrik Jarrsten is Ex CFO of Orexo AB ADR
Age 56
Phone46 1 87 80 88 00
Webhttps://www.orexo.com

Orexo AB Management Efficiency

The company has return on total asset (ROA) of (0.0965) % which means that it has lost $0.0965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6535) %, meaning that it generated substantial loss on money invested by shareholders. Orexo AB's management efficiency ratios could be used to measure how well Orexo AB manages its routine affairs as well as how well it operates its assets and liabilities.
Orexo AB ADR has accumulated 492.3 M in total debt with debt to equity ratio (D/E) of 1.76, which is about average as compared to similar companies. Orexo AB ADR has a current ratio of 2.01, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Orexo AB until it has trouble settling it off, either with new capital or with free cash flow. So, Orexo AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Orexo AB ADR sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Orexo to invest in growth at high rates of return. When we think about Orexo AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

INSIDER Age

Alain BellemareDelta Air Lines
63
Raul PascualCopa Holdings SA
N/A
Julianne CanavaggioCopa Holdings SA
38
Robert RivkinUnited Airlines Holdings
63
Peter DonkerslootCopa Holdings SA
36
Rebecca AretosAllegiant Travel
48
Bill DykesSkyWest
N/A
Robert NealAllegiant Travel
39
Sonya WolfordSkyWest
N/A
Orexo AB , a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Orexo AB was incorporated in 1994 and is headquartered in Uppsala, Sweden. OREXO AB is traded on OTC Exchange in the United States. Orexo AB ADR [ORXOY] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Return On Equity-0.65
Return On Asset-0.0965

Orexo AB ADR Leadership Team

Elected by the shareholders, the Orexo AB's board of directors comprises two types of representatives: Orexo AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orexo. The board's role is to monitor Orexo AB's management team and ensure that shareholders' interests are well served. Orexo AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orexo AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
Fredrik Jarrsten, Ex CFO
MD MBA, Chief Officer
Cecilia Coupland, Vice President and Head of Operations
Nikolaj Sorensen, Pres CEO
Lena Wange, Investor Relations & Communications Manager
Jesper Lind, Advisor
Dennis Urbaniak, Ex Therapeutics
Robert DeLuca, President of Orexo US Inc.
Robert Ronn, Vice President and Head of Research & Development

Orexo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Orexo AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.65
Return On Asset-0.0965
Profit Margin(0.28) %
Current Valuation76.98 M
Shares Outstanding34.35 M
Price To Earning17.22 X
Price To Book2.06 X
Price To Sales1.00 X
Revenue565 M
Gross Profit521.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Orexo OTC Stock Analysis

When running Orexo AB's price analysis, check to measure Orexo AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orexo AB is operating at the current time. Most of Orexo AB's value examination focuses on studying past and present price action to predict the probability of Orexo AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orexo AB's price. Additionally, you may evaluate how the addition of Orexo AB to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY